NCTN Deep South Research Consortium

NCTN 深南研究联盟

基本信息

批准号：
10159225
负责人：
MARY-ANN BJORNSTI
金额：
$ 53.27万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-03-06 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10159225
关键词：
Achievement Address Alabama American College of Radiology Imaging Network Area Arkansas Basic Science Cancer Biology Cancer Control Cancer Patient Cancer and Leukemia Group B Clinical Cancer Center Clinical Investigator Clinical Research Clinical Trials Clinical Trials Cooperative Group Clinical Trials Network Communities Community Outreach Comprehensive Cancer Center Cooperative Group Program Country Deep South Detection Diagnosis Doctor of Medicine Doctor of Philosophy Eastern Cooperative Oncology Group Enrollment Ensure Faculty Fostering Funding Gynecologic Oncology Group Home Hospitals Infrastructure Intention International Intervention Investigational Therapies Knowledge Lead Leadership Louisiana Malignant Neoplasms Mentors Minority Minority Participation Mississippi Names National Clinical Trials Network National Surgical Adjuvant Breast and Bowel Project Outcome Patients Phase Physicians Process Quality of life Radiation Therapy Oncology Group Recording of previous events Research Research Personnel Research Training Role Scientist Site Socioeconomic Status Southwest Oncology Group Training Training Programs Training and Infrastructure Translating Translational Research United States Universities Vision Work anticancer research cancer care cancer clinical trial cancer health disparity cancer prevention cancer risk clinical trial participant demographics ethnic minority population health disparity interest member minority health minority scientist next generation organizational structure patient population population based programs racial health disparity recruit survivorship translational scientist treatment trial

项目摘要

The University of Alabama at Birmingham Comprehensive Cancer Center (UAB CCC) has a long history of participation within the nation's cancer related Clinical Trials Cooperative Group Program. Specifically, UAB was a founding member of the GOG, and has been a member of RTOG, ECOG, ACRIN. CALGB, NSABP, and SWOG. UAB CCC is a current member of the ALLIANCE, ECOG-ACRIN, NRG and SWOG cooperative groups. The UAB NCTN Deep South Research Consortium (DSRC) is currently a Lead Academic Participating Site in the NCI's National Clinical Trials Network (NCTN) Program, and now submits this proposal to continue to serve the NCI in this capacity. It is our intention to continue as a leading contributor of scientific leaders and clinical trial participants to the NCTN Program in the U.S. and particularly in the Southeast. To accomplish this overall vision, we propose the following specific aims: 1) To further enhance the involvement of existing UAB CCC scientific leadership in NCTN Cooperative Group related clinical and translational research and to develop the next generation of NCTN Cooperative group scientific leaders within the UAB CCC, and 2) To further refine a clinical trials process within the DSRC that optimizes accrual of potentially eligible cancer patients and patients at risk for cancer to NCTN Cooperative Group clinical trials, and 3) To further increase minority accrual to NCTN Cooperative Group trials. We include in this proposal a detailed description of our DSRC cooperative group scientific and patient accrual contributions and accomplishments, a leadership and organizational structure for our Consortium, and how we intend to utilize existing DSRC infrastructure to achieve our aims. Further, we also include a detailed description of our Junior Investigator Recruitment and Mentoring Program.

伯明翰综合癌症中心（UAB CCC）的阿拉巴马大学有很长的美国癌症相关临床试验的参与历史合作小组程序。具体而言，UAB是GOG的创始成员，并且是 RTOG，ECOG，ACRIN。 CALGB，NSABP和SWOG。 UAB CCC是现任成员联盟，Ecog-Acrin，NRG和Swog合作团体。 UAB NCTN南部研究联盟（DSRC）目前是NCI的主要学术参与地点国家临床试验网络（NCTN）计划，现在提交此建议继续以这种身份服务NCI。我们打算继续作为科学的主要贡献者 NCTN计划的领导者和临床试验参与者，尤其是在东南。为了实现这一整体愿景，我们提出以下特定目的：1）进一步增强NCTN合作集团现有UAB CCC科学领导的参与相关的临床和转化研究，并发展下一代NCTN UAB CCC中的合作小组科学领导者和2）进一步完善临床试验 DSRC中的过程优化了潜在符合条件的癌症患者和患者 NCTN合作组临床试验的癌症风险，3）进一步增加少数 NCTN合作小组试验应计。我们在此提案中包括我们的DSRC合作团体科学和患者应计贡献和成就，我们财团的领导和组织结构，以及我们打算如何利用现有 DSRC基础设施实现我们的目标。此外，我们还包括了我们的详细描述初级调查员招聘和指导计划。